Reggie E. Duerst, MD

Director, Stem Cell Transplant Program

Associate Professor of Pediatrics, Northwestern University Feinberg School of Medicine

Appointments & Referrals

1.800.543.7362 (1.800.KIDS DOC)

About Me

Clinical Interests: Stem cell transplantation; cancer survivorship; stem cell transplantation outcomes research

Specialties, Programs & Conditions

Specialties:

Hematology & Oncology

Programs & Conditions:

Stem Cell Transplantation Program

Education & Training

Education: University of Wisconsin, Madison, 1979

Postgraduate Training: University of Rochester School of Medicine & Dentistry, 1987; University of Minnesota Health Sciences Center, 1986; Strong Memorial Hospital, 1982

Board Certifications: Pediatric Hematology-Oncology, General Pediatrics

Publications

Most recent publications

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure Blood127 (13): 1656-65
Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation Biol Blood Marrow Transplant21 (9): 1612-21
Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: improved outcomes for de novo disease Pediatr Transplant15 (3): 334-43
Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant Bone Marrow Transplant44 (3): 145-56
Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant Pediatr Blood Cancer64 (9):
IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients Bone Marrow Transplant51 (10): 1394-1396
Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy Leuk Lymphoma57 (4): 949-52
High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival Br J Haematol146 (6): 669-74
Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease Hematol Oncol Stem Cell Ther11 (3): 169-174
A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors J Neurooncol97 (2): 247-55

Reggie E. Duerst, MD

Reggie E. Duerst, MD

Director, Stem Cell Transplant Program

Associate Professor of Pediatrics, Northwestern University Feinberg School of Medicine

Appointments & Referrals

1.800.543.7362 (1.800.KIDS DOC)

About Me

Specialties, Programs & Conditions

Education & Training

Publications

Call 1.800.543.7362 for Insurance information. 1.800.543.7362

Location